NEW TAIPEI CITY, Taiwan — Apr. 22, 2026 – Winnoz, a leader in advanced microsampling technology, is proud to announce that its next-generation Haiim® Plus system and Cassette-X™ have officially received CE Mark approval. This certification marks a pivotal moment in the company’s mission to standardize blood collection worldwide.
Solving the “Last Mile” of Decentralized Diagnostics
This milestone clears the path for our large-scale commercial rollout. We are solving the “last mile” problem of decentralized diagnostics with data-backed results:
- Unmatched Collection Reliability: A major leap in success rates for a significant jump in success rates for large-volume sampling.
- Durability at Scale: With a durability of 20,000+ uses per device ensures market-ready economics.
- Real-World Impact: Expanding from 100 to 600+ pharmacy locations in Germany this year alone.
Availability & Shipping
Shipping for the Haiim® Plus and Cassette-X™ will commence in late April 2026.
About Winnoz
Founded in New Taipei City, Taiwan, Winnoz Technology, Inc. develops innovative microsampling and molecular diagnostic technologies that enable decentralized healthcare. Its flagship Haiim® system is recognized globally for ease of use, accuracy, and the ability to bring blood testing closer to patients.
For more information, visit www.winnoz.com or follow Winnoz on LinkedIn at www.linkedin.com/company/winnoz-technology/.
Trademarks: Haiim®, and Cassette-X™ are registered trademarks of Winnoz Technology, Inc.
#ClinicalDiagnostics #SeriesA #HealthInnovation #Biotech #Winnoz
Strategic Partnerships
We invite global distributors, diagnostic labs, and investors to join us in this expansion. To discuss partnership or investment opportunities, please contact:
David Huang, Ph.D.
Chief Partnership & Business Development Officer (CPBDO)
Email: david959@winnoz.com
